3. Treatment of ACS Part 2 (Working Diagnosis of STEMI vs NSTE ACS, Arabic Version)
Vložit
- čas přidán 4. 07. 2024
- In this video, the specific recommedations regarding the indications for revascularization and for pharmacotherapy are compared in the working diagnosis of STEMI vs. NSTE-ACS.
0:00 Reperfusion Indications in STEMI
9:17 Pharmacotherapy in STEMI
12:49 Fibrinolytic Therapy for STEMI
19:53 Reperfusion Indications in NSTE-ACS
22:53 Pharmacotherapy in NSTE-ACS
2023 ESC Guidelines for the Management of Acute Coronary Syndromes
www.escardio.org/Guidelines/C...
2023 ESC Guidelines for the management of acute coronary syndromes Supplementary data
oup.silverchair-cdn.com/oup/b...
Percutaneous Myocardial Revascularization in Late-Presenting Patients With STEMI
pubmed.ncbi.nlm.nih.gov/34556...
Mechanical Reperfusion and Long-term Mortality in Patients With Acute Myocardial Infarction Presenting 12 to 48 Hours From Onset of Symptoms.
jamanetwork.com/journals/jama...
Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial
www.ncbi.nlm.nih.gov/pmc/arti...
ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up
pubmed.ncbi.nlm.nih.gov/25161...
Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction. STREAM trial
www.nejm.org/doi/full/10.1056...
Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme
pubmed.ncbi.nlm.nih.gov/31539...
ISAR-REACT 5 trial. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
pubmed.ncbi.nlm.nih.gov/31475...
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction
pubmed.ncbi.nlm.nih.gov/11530...
GRACE ACS Risk and Mortality Calculator
www.mdcalc.com/calc/1099/grac...
Thanks